Company intelligence / Profile preview

Shenyang Sunshine Pharmaceutical Co., LTD.

Shenyang, Liaoning, China

Ownership: Private
Employees: ~1000
Development stage: Other

Overview

Phase 3 trial of nofazinlimab (anti-PD-1) in first-line hepatocellular carcinoma completed enrollment, with topline results expected; DB-1303 (HER2 ADC) in pivotal Phase 3 for breast cancer in China. Several recombinant biologics and biosimilars are marketed for hematology and infectious diseases.

Therapeutic areas: OncologyInfectious DiseasesHematologyOphthalmology
Modalities: Monoclonal antibodyBispecific antibodyBiosimilarSmall moleculeProtein therapeuticsSynthetic proteinColony-stimulating factorBiological productAntibody-drug conjugate
Industry: Biotech

Drug pipeline

6 assets

SSGJ-612

5 more assets in the full pipeline.

Request access →

Partnerships

CStone PharmaceuticalsDuality BiologicsAstraZeneca

Beyond the preview

Go deeper on Shenyang Sunshine Pharmaceutical Co., LTD..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shenyang Sunshine Pharmaceutical Co., LTD..

Explore the full profile